Skip to main content

Table 2 Comparison of subjects with and without colistin-resistant E. coli or K. pneumoniae colonization during the study period

From: Collateral damage of using colistin in hospitalized patients on emergence of colistin-resistant Escherichia coli and Klebsiella pneumoniae colonization and infection

Variables Colonization
(n = 66)
No Colonization
(n = 73)
p-value
Female gender (yrs), n (%) 33 (50.0%) 37 (50.7%) 0.94
Age (yrs), mean ± SD 65.7 ± 16.7 68.5 ± 15.1 0.32
Duration from hospital admission to first sample collection (days), median (range) 16 (1–106) 16 (2–81) 0.37
Duration from enrollment to first sample collection (days), median (range) 1 (1–4) 1 (1–5) 0.54
ICU admission, n (%) 24 (36.4%) 24 (32.9%) 0.67
Previous hospitalization, n (%) 36 (54.5%) 37 (50.7%) 0.65
APACHE II score at study enrollment, mean ± SD 21.6 ± 7.1 21.9 ± 7.6 0.77
Mechanical ventilation, n (%) 59 (89.4%) 58 (79.5%) 0.11
Indwelling central venous catheter, n (%) 45 (68.2%) 40 (54.8%) 0.11
Surgery, n (%) 45 (68.2%) 39 (53.4%) 0.08
Chronic intermittent hemodialysis, n (%) 8 (12.1%) 10 (13.7%) 0.78
Antibiotic use for the current hospitalization prior to study enrollment and during study period, n (%)
 Carbapenems 57 (86.4%) 66 (90.4%) 0.46
 Cephalosporins 31 (47.0%) 31 (42.5%) 0.59
 Beta-lactam/ beta-lactamase inhibitors 54 (81.8%) 52 (71.2%) 0.14
 Fluoroquinolones 42 (63.6%) 33 (45.2%) 0.03
 Vancomycin 40 (60.6%) 38 (52.1%) 0.31
 Aminoglycosides 10 (15.2%) 2 (2.7%) < 0.001
Antibiotic use for the current hospitalization prior to study enrollment, n (%)
 Carbapenems 52 (78.8%) 60 (82.2%) 0.61
 Cephalosporins 26 (39.4%) 30 (41.1%) 0.84
 Beta-lactam/beta-lactamase inhibitors 37 (56.1%) 38 (52.1%) 0.64
 Fluoroquinolones 24 (36.4%) 15 (20.5%) 0.04
 Vancomycin 22 (33.3%) 21 (28.8%) 0.56
 Aminoglycosides 5 (7.6%) 1 (1.4%) 0.10
Colistin use within 3 months prior to study enrollment, n (%) 13 (19.7%) 2 (2.7%) 0.001
Total amount of colistin (mg), median (range) 3550 (400–12,550) 2000 (500–10,650) < 0.001
Total duration of colistin use (days), median (range) 13.5 (2–58) 9 (2–32) < 0.001
Total courses of colistin therapy, mean ± SD 1.4 ± 0.8 1.1 ± 0.4 0.003
Total courses of colistin therapy, range 1–4 1–3  
Patients who received more than 1 course of colistin therapy, n (%) 19 (28.8%) 7 (9.6%) 0.004
Length of hospital stay (days), median (range) 46.5 (12–246) 32 (6–192) 0.01
All-cause mortality at hospital discharge, n (%) 35 (53.0%) 35 (47.9%) 0.55